


*“Current Market Scenario of
Plasma Products among
Paediatric Segment in India”*

INTRODUCTION

Plasma items have demonstrated an amazing blast during the most recent year. Even though revelation of recombinant item has tested clearly inferred plasma protein practice anyway in any case in creating nation like India, Plasma item is picking up notoriety because of their higher worthiness through senior people.

Reason for development of plasma item are a result of employments in new sign, better-cleaning, developing worry among Indian Biopharmaceutical Industry like Reliance, Intas, Bharat Serum, and so on., subsequently heaps of Biopharmaceutical Businesses are venturing into this stage and for viable propelling of their item and picking up the most extreme commercial centre extent, business people are hoping to find the endorsing behaviour and example of clinical specialists.



PLASMA JOURNEY



PlasmaGen BioSciences Pvt. Ltd.

Is an Indian Biopharmaceutical company specializing in Plasma Protein Therapy. We pursue a vision of ushering in the Plasma Protein industry in India & SAARC nations. PGB aims to provide a wide range of safe plasma products to improve the health & quality of life of patients.

PlasmaGlob[®]
Intravenous Immunoglobulin 5gm, 2.5gm & 0.5gm

PlasmaRho
Polyclonal Anti-D Immunoglobulin

GammaFact-VIII
Anti-Haemophilic Factor VIII, Concentrated, Human I.P. 250 I.U.

PlasmaHep
Human Hepatitis B Immunoglobulin

PlasmaRAB
Human Rabies Immunoglobulin E.P.
150 IU/mL (300 IU/Vial)

Rh₀(D) Immune Globulin(Human) E.P.
PlasmaRho-D I.V.

AlbuMax
Human Albumin 20% I.P.

***Exciting Offers Available For PlasmaHep On MediBox**

For Further Info: ☎ +91 8077 198 556
☎ +91 7042 632 832

PlasmaGen
Biosciences
www.plasmagen.in

IVIG INDICATIONS FDA APPROVED

**Primary
Immunodeficiency
Diseases (PID)**

**Idiopathic
Thrombocytopenic
Purpura (ITP)**

**Chronic
Lymphocytic
Leukemia (CLL)**

**Chronic
Inflammatory
Demyelinating
Polyneuropathy
(CIDP)**

**Kawasaki Disease
(KD)**

**Guillain-Barre
Syndrome (GBS)**

OBJECTIVE

To understand the wide range of IVIG in different indications.

To access the Global & Indian Market of IVIG.

To determine the market share of different brands of medicine available in market.

RESEARCH METHODOLOGY

Type of Research: -
Descriptive Study.

Duration of Study: - Three
Months (03/02/2020 to
02/05/2020)


Tool: - MS-Excel

Method of Data Collection: -
The secondary data for
competitor analysis and market
developments have been used.

Source of Secondary Data: - An expansive cluster of industry hotspots for our optional examination was liked, which by and large incorporate not constrained to:

- Company sites, organization yearly reports, budgetary reports and financial specialist introduction for serious situation and state of the business.
- For item data and related pre-emption, the logical and specialized compositions were utilized.
- For showcase assessment the legitimate new articles, webcasts and other related discharges were utilized.
- Key showcase pointers and important official statements for advertise gauges and estimate both Internal and outer restrictive databases.

Global Intravenous Immunoglobulins Market Size, 2015-2025 (USD Million)




www.fortunebusinessinsights.com

Global Market Overview

BY GEOGRAPHY GLOBAL IVIG MARKET

INTRAVENOUS IMMUNOGLOBULINS MARKET

North America Intravenous Immunoglobulins Market, 2017



Global Intravenous Immunoglobulins Market (US\$ Mn), 2017 to 2025


2017

9,787.6Mn

2025

15,789.1 Mn

Global Intravenous Immunoglobulins Market Share, By Indication, 2017



Copyrights © Fortune Business Insights | www.fortunebusinessinsights.com

Global Primary Immunodeficiency Diseases Treatment Market Geographical Segmentation

GLOBAL PRIMARY IMMUNODEFICIENCY DISEASES TREATMENT MARKET GEOGRAPHICAL SEGMENTATION

Global Primary Immunodeficiency Diseases Treatment Market By Geography 2016 (% share)




The PIDDs treatment market in the Americas was valued at \$2,009.44 million in 2016.

The PIDDs treatment market in EMEA is expected to reach \$1,563.09 million by 2021.

The PIDDs treatment market in APAC is growing at a CAGR of 6.35%.

China, Australia, Japan, and India contribute to the major share of the market in APAC.

Global intravenous immunoglobulin market, by route of administration, 2016 (%)




***IVIg ROUTE OF
ADMINISTRATION***

GRIFOLS IVIG MARKET SHARE


Grifols maintains the leading IVIG global market share

**IV and SubQ Immunoglobulin
(value)**



GRIFOLS CSL BAXTER OCTAPHARMA
KEDRION BIOTEST LFB OTHERS

**IVIG market
(value)**




Source: Internal data, MRB & Secondary official data year 2014



***CHINA
MARKET***

MARKET SHARE OF GLOBAL COMPANY



*GLOBAL
COMPANIES
MARKET
SHARE*


IVIG PRODUCT IN GLOBAL MARKET

Sl.no	COMPANY NAME	BRAND NAME	CONCENTRATION	SIZES
1	CSL Behring	Carimune NF	3%,6%,9%,12%	3g, 6g, 12g
2	Grifols	Flebogamma 5% DIF	5%	2.5g, 5g, 10g, 20g
3	Grifols	Flebogamma 10% DIF	10%	5g, 10g, 20g
4	Shire	Gammagard	5%, 10%	5g, 10g
5	Bio Product Lab	Gammaplex 5%	5%	5g, 10g, 20g
6	Bio Product Lab	Gammaplex 10%	10%	5g, 10g, 20g
7	Octapharma	Octagam 5%	5%	1g,2.5g,5g,10g, 25g
8	Octapharma	Octagam 10%	10%	2g, 5g, 10g, 20g
9	Octapharma	Privigen	10%	5g, 10g, 20g, 40g

INDIAN COMPANY OF IVIG MARKET

Sl. No	COMPANY NAME	BRAND NAME	STRENGTH	MRP
1	Reliance Life Sciences	Immunorel	5%	₹ 15,500
2	Reliance Life Sciences	Immunorel	5%	₹ 15,500
3	Intas	Globucel	5%	₹ 15,780
4	Intas	Globucel	10%	₹ 15,853
5	PlasmaGen	PlasmaGlob	5%	₹ 15,780
6	PlasmaGen	PlasmaGlob	10%	₹ 18,990
7	Bharat Serum	Gamma IV	5%	₹ 10,500
8	Biocon	Ivnex	5%	₹ 7,334
9	Emcure	Emglobulin	5%	₹ 12,000
10	Zydus	Octagam	5%	₹ 12,000

■ Reliance ■ Intas ■ PlasmaGen ■ Wockhardt ■ India Bulls ■ Blocon ■ Bharat Serum



***MARKET
COVERAGE
BY INDIAN
COMPANIES***

R_x

PlasmaGlob[®]

Intravenous Immunoglobulin 0.5gm/10ml, 2.5g/50ml & 5g/100 ml



CONCLUSION

- The wide scope of IVIG in various signs was comprehended to realize the utilization example and it was for the most part utilized in FDA affirmed signs and off mark signs.
- To Global and Indian Market of IVIG was gotten to for the most part by North America, trailed by EMEA, APAC and China Market universally and Indian market essentially was led by Albumin, IVIG, Factor VIII and IX.
- The principle piece of the overall industry of various brands of medication accessible in Global market are Grifols, CSL, and Baxter and Indian market is Reliance, Intas, PlasmaGen and wockhardt.

Many doctors rely on price factor because cost of IVIG therapy is very high especially in government hospital so here the price is the important criteria for making brand successful, so price should be economical.

Based on its application in the treatment of several conditions i.e. CIDP, ITP, PID, secondary Immunodeficiency in Chronic Lymphocytic Leukemia, the global IVIG market is segmented Pediatric Human Immunodeficiency Virus (HIV) infection, Kawasaki Disease, Specific antibody Deficiency, Acquired Hypogammaglobinemia, Myasthenia Gravis so we can easily segregate the market and segregate the potential customers like hematology, neurology, rheumatology, intensivist.

Active promotion of products by the companies to these doctors like Neuro Physician and Hemato Oncologist as they are using IVIG in rare disorders.

Awareness about the recent advance in plasma product and usage in newer indications can be done by providing Medical Literature to the doctors.



RECOMMENDATION

PRESENTED BY,

*Lajwanthi Sharma
MBA PM 10
Roll No. - 135
IIHMR University
Jaipur*

*Thank
you*

